Northland Securities Analysts Give Adamas Pharmaceuticals (NASDAQ:ADMS) a $15.00 Price Target

Adamas Pharmaceuticals (NASDAQ:ADMS) has been given a $15.00 price target by research analysts at Northland Securities in a note issued to investors on Friday, TipRanks reports. The firm currently has a “buy” rating on the specialty pharmaceutical company’s stock. Northland Securities’ price objective indicates a potential upside of 136.97% from the company’s current price.

Several other research analysts have also recently weighed in on the company. Evercore ISI reaffirmed a “buy” rating and set a $55.00 target price on shares of Adamas Pharmaceuticals in a research note on Monday, August 12th. HC Wainwright decreased their target price on Adamas Pharmaceuticals from $40.00 to $30.00 and set a “buy” rating for the company in a research note on Tuesday, May 28th. Cowen set a $5.00 target price on Adamas Pharmaceuticals and gave the company a “hold” rating in a research note on Friday, August 9th. Cantor Fitzgerald started coverage on Adamas Pharmaceuticals in a research note on Monday, September 9th. They set a “neutral” rating and a $8.00 target price for the company. Finally, Zacks Investment Research raised Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, August 13th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and five have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $19.13.

ADMS stock traded up $0.09 during trading hours on Friday, hitting $6.33. 1,260,122 shares of the stock traded hands, compared to its average volume of 321,176. The stock has a 50-day simple moving average of $6.11 and a 200 day simple moving average of $6.37. Adamas Pharmaceuticals has a one year low of $4.20 and a one year high of $22.55. The company has a market cap of $173.29 million, a P/E ratio of -1.30 and a beta of 1.62. The company has a current ratio of 7.27, a quick ratio of 7.05 and a debt-to-equity ratio of 3.05.



Adamas Pharmaceuticals (NASDAQ:ADMS) last announced its earnings results on Thursday, August 8th. The specialty pharmaceutical company reported ($0.90) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.98) by $0.08. Adamas Pharmaceuticals had a negative return on equity of 149.97% and a negative net margin of 241.41%. The business had revenue of $12.69 million during the quarter, compared to analysts’ expectations of $12.62 million. Analysts forecast that Adamas Pharmaceuticals will post -3.63 earnings per share for the current year.

Several large investors have recently added to or reduced their stakes in ADMS. BNP Paribas Arbitrage SA acquired a new position in shares of Adamas Pharmaceuticals in the 1st quarter valued at $33,000. SG Americas Securities LLC boosted its position in shares of Adamas Pharmaceuticals by 37.5% in the 1st quarter. SG Americas Securities LLC now owns 33,766 shares of the specialty pharmaceutical company’s stock valued at $240,000 after purchasing an additional 9,213 shares during the period. Fosun International Ltd boosted its position in shares of Adamas Pharmaceuticals by 13.7% in the 1st quarter. Fosun International Ltd now owns 223,959 shares of the specialty pharmaceutical company’s stock valued at $1,610,000 after purchasing an additional 27,000 shares during the period. Granite Investment Partners LLC acquired a new position in shares of Adamas Pharmaceuticals in the 1st quarter valued at $304,000. Finally, Healthcare Value Capital LLC acquired a new position in shares of Adamas Pharmaceuticals in the 1st quarter valued at $711,000. Institutional investors and hedge funds own 63.44% of the company’s stock.

Adamas Pharmaceuticals Company Profile

Adamas Pharmaceuticals, Inc focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.

Featured Story: Stock Portfolio Tracker

Analyst Recommendations for Adamas Pharmaceuticals (NASDAQ:ADMS)

Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.